PegIntron is a pet medicine, also known as pet PegIntron interferon. The reasons for its discontinuation may be as follows:

Technical update: As a biological agent, the production of PegIntron interferon requires a high level of technology and strict quality control. However, with the rapid development of biotechnology at home and abroad, some more advanced and efficient alternatives have continued to emerge, making PegIntron's competitiveness in the market gradually weakened.

Changes in market demand: As the level of pet medical treatment improves, pet owners' demand for pet medication is also constantly changing. Some new pet medicines are not only more effective, but also have fewer side effects, so they are favored by pet owners. In contrast, the advantages of PegIntron Interferon in some aspects are no longer obvious, and market demand will naturally decline.

Policy adjustment: In recent years, the state has continuously strengthened its supervision of drug production, and its requirements for drug quality have become higher and higher. Some manufacturers that do not comply with the regulations or cannot meet the new standards may face the risk of rectification or closure. If the manufacturer of PegIntron interferon commits violations during the production process or fails to meet new quality standards, a production shutdown will be inevitable.